Divalproex Sodium
Product Images NDC 55648-725

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55648-725). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium (Discription01)

Chemical structure of divalproex sodium active ingredient as shown in the image, depicting its molecular arrangement with sodium ion and valproic acid components. The structure highlights the sodium salt form relevant to the drug product by Wockhardt Limited.*

FDA Label Image

100 Tablets Container Label (Divalproex Sodium Er Tablets 250 mg 100 Tablets Label)

Label for Divalproex Sodium Extended-Release Tablets 250 mg showing product name, strength, and dosage form. The label states 100 tablets per container and includes manufacturer information for Wockhardt Limited, Mumbai, India, and distributor Wockhardt USA LLC. It also includes handling instructions, barcode, and a NON VARNISH AREA section.*

FDA Label Image

100 Tablets Container Label (Divalproex Sodium Er Tablets 500 mg 100 Tablets Label)

Label for Divalproex Sodium Extended-Release Tablets 500 mg, containing 100 tablets per container. The label includes dosage strength, NDC 64679-725-02, and instructions to dispense with a patient information sheet. It is manufactured by Wockhardt Limited, Mumbai, India, and distributed by Wockhardt USA LLC. The label also notes proper storage and tamper-evident sealing information.*

FDA Label Image

Figure 1 (Figure01)

A cumulative response curve plot showing the percentage reduction in CPS rate versus percentage of patients. The chart compares Divalproex Sodium Delayed-Release Tablets with Placebo, illustrating patient improvements and worsening effects along the Y-axis from -100% to 100% reduction in CPS rate and the X-axis representing patient percentage from 100% to 0%.*

FDA Label Image

Figure 2 (Figure02)

A cumulative distribution plot showing the percent reduction in CPS rate versus percent of patients for two groups: high dose Divalproex Sodium delayed-release tablets and low dose Divalproex Sodium delayed-release tablets. The vertical axis represents percent reduction (improvement or worsening) in CPS rate, and the horizontal axis represents the percent of patients.*

FDA Label Image

Figure 3 (Figure03)

A bar graph comparing placebo and Divalproex Sodium Extended Release Tablets with numerical labels on each bar. The graph shows the placebo value at 0.6 and the Divalproex Sodium value at 1.2, marked with a significance indicator (*p=0.006). The x-axis categorizes placebo versus Divalproex Sodium extended-release tablets, and the y-axis displays a numeric scale from 0 to 1.2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.